Metformin targets multiple signaling pathways in cancer
10.1186/s40880-017-0184-9
- Author:
Lei YONG
1
;
Yi YANHUA
;
Liu YANG
;
Liu XIA
;
Keller T. EVAN
;
Qian CHAO-NAN
;
Zhang JIAN
;
Lu YI
Author Information
1. Key Laboratory of Longevity and Ageing-related Diseases
- Keywords:
Metformin;
Signaling pathway;
Cancer stem cell;
Cancer
- From:Chinese Journal of Cancer
2017;36(7):289-297
- CountryChina
- Language:Chinese
-
Abstract:
Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 dia-betes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addi-tion, cutting-edge targeting of cancer stem cells by metformin is summarized.
